Srdan Verstovsek MDChief, Section for Myeloproliferative Neoplasms, Leukemia Department, Department of Leukemia, Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dr Srdan Verstovsek is a medical oncologist and professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. He obtained his medical and doctoral degree at the University of Zagreb, Zagreb, Croatia. Dr Verstovsek’s clinical and translational research is focused on understanding the biology of and developing new therapies for myeloproliferative neoplasms (MPNs). He is Director of the Clinical Research Center for MPNs at MD Anderson. He has been principal investigator for more than 50 clinical trials testing novel therapies for patients with MPNs and has published more than 400 peer-reviewed manuscripts. Dr Verstovsek is actively involved with national patient groups and is a frequently invited speaker on MPNs both nationally and internationally. In 2010, he was awarded the Celgene 2010 Young Investigator Award for Clinical Research in Hematology, and in 2011, he was awarded the Distinguished Alumnus Award, Division of Cancer Medicine, MD Anderson. In 2013, Dr Verstovsek was awarded the 7th Annual Irwin H. Krakoff Award for Excellence in Clinical Research by the Division of Cancer Medicine, MD Anderson, and the Distinguished Lecturer Award from the Society of Hematologic Oncology. In 2015, Dr Verstovsek was elected as a member of The American Society for Clinical Investigation in recognition of his contributions as a physician-scientist. In 2017, Dr Verstovsek was awarded the Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research by MD Anderson Cancer Center.
DisclosuresDr. Verstovsek reports the following research support:
- Incyte Corporation
- Lilly Oncology
- NS Pharma
- Bristol Myers Squibb
- Seattle Genetics
- CTI BioPharma Corp.
- Galena BioPharma
- Blueprint Medicines Corp.
Recent Contributions to PracticeUpdate:
- Diagnostic Performances of Serum Erythropoietin Level and JAK2 Mutation for Polycythemias
- Leukemic Evolution of Polycythemia Vera and Essential Thrombocythemia
- Approach to Myelofibrosis Post JAK Inhibitor Failure
- Nonadherence to Cytoreductive and/or Antithrombotic Drugs Is Associated With an Increased Risk of Complications in Polycythemia Vera or Essential Thrombocythemia